These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 32202557)

  • 1. [PCSK9 inhibitor use in high cardiovascular risk patients: an interventionalist's overview on efficacy, current recommendations and factual prescription].
    Masiero G; Franzone A; Silvestri T; Castiglioni B; Greco F; La Manna AG; Limbruno U; Longoni M; Marchese A; Mattesini A; Mauro C; Rigattieri S; Tarantino FF; Esposito G; Musumeci G; Tarantini G
    G Ital Cardiol (Rome); 2020 Apr; 21(4):264-270. PubMed ID: 32202557
    [No Abstract]   [Full Text] [Related]  

  • 2. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [PCSK9 inhibitors: how to bridge the gap between scientific evidence and regulatory barriers?].
    Cortese B; Di Palma G; Lettieri C; Musumeci G
    G Ital Cardiol (Rome); 2018 Feb; 19(2):77-80. PubMed ID: 29531379
    [No Abstract]   [Full Text] [Related]  

  • 4. [PCSK9 inhibitors: For which patients? For which indication? What to consider?].
    Busygina K; Parhofer KG
    MMW Fortschr Med; 2018 Jan; 160(1):43-46. PubMed ID: 29335943
    [No Abstract]   [Full Text] [Related]  

  • 5. Pleiotropic Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors?
    Bittner V
    Circulation; 2016 Nov; 134(22):1695-1696. PubMed ID: 27895023
    [No Abstract]   [Full Text] [Related]  

  • 6. PCSK9: is it fluoride for cardiology?
    King SB
    JACC Cardiovasc Interv; 2014 Nov; 7(11):1331-2. PubMed ID: 25459045
    [No Abstract]   [Full Text] [Related]  

  • 7. [Consensus document of the Spanish Society of Arteriosclerosis on indications of inhibitors of PCSK9].
    Masana L; Ascaso JF; Civeira F; Pedro-Botet J; Valdivielso P; Guijarro C; Mostaza J; López Miranda J; Pintó X;
    Clin Investig Arterioscler; 2016; 28(3):164-5. PubMed ID: 26976748
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drugs that Mimic the Effect of Gene Mutations for the Prevention or the Treatment of Atherosclerotic Disease: From PCSK9 Inhibition to ANGPTL3 Inactivation.
    Athyros VG; Katsiki N; Dimakopoulou A; Patoulias D; Alataki S; Doumas M
    Curr Pharm Des; 2018; 24(31):3638-3646. PubMed ID: 30306859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dyslipidaemia: Anti-PCSK9 vaccines to halt atherosclerosis.
    Ummarino D
    Nat Rev Cardiol; 2017 Aug; 14(8):442-443. PubMed ID: 28682322
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of PCSK9 antibodies in cardiovascular disease: Critical considerations of mortality and neurocognitive findings from the current literature.
    Kołodziejczak M; Navarese EP
    Atherosclerosis; 2016 Apr; 247():189-92. PubMed ID: 26926598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables.
    Filippatos TD; Kei A; Rizos CV; Elisaf MS
    J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):3-12. PubMed ID: 28826253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dyslipidaemia: No effect of PCSK9 inhibitors on cognitive function.
    Fernández-Ruiz I
    Nat Rev Cardiol; 2017 Oct; 14(10):568. PubMed ID: 28857083
    [No Abstract]   [Full Text] [Related]  

  • 14. Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options.
    Berman AN; Blankstein R
    Curr Cardiol Rep; 2019 Aug; 21(9):110. PubMed ID: 31378838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Therapeutic Approaches to the Treatment of Dyslipidemia.
    Rader DJ
    Cell Metab; 2016 Mar; 23(3):405-12. PubMed ID: 26853751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Not Available].
    Riesen WF
    Praxis (Bern 1994); 2017 Aug; 106(17):921-926. PubMed ID: 28830328
    [No Abstract]   [Full Text] [Related]  

  • 17. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging PCSK9 inhibitors for treating dyslipidaemia: buttressing the gaps in coronary prevention.
    Page MM; Watts GF
    Expert Opin Emerg Drugs; 2015 Jun; 20(2):299-312. PubMed ID: 25861882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of proprotein convertase subtilisin/kexin 9 inhibitors in people with diabetes and dyslipidaemia.
    Dijk W; Cariou B
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 1():39-51. PubMed ID: 31002456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New developments in atherosclerosis: clinical potential of PCSK9 inhibition.
    Giunzioni I; Tavori H
    Vasc Health Risk Manag; 2015; 11():493-501. PubMed ID: 26345307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.